Ocugen (OCGN) announced that dosing is complete, ahead of schedule in the Phase 2 portion of the Phase 1/2 ArMaDa clinical trial for OCU410-a novel multifunctional modifier gene therapy candidate being developed for geographic atrophy, an advanced stage of dry age-related macular degeneration. In the Phase 2 study, the safety and efficacy of OCU410 in patients with GA secondary to dAMD will be assessed. Fifty-one patients were randomized 1:1:1 into either of two treatment groups or a control group. In the treatment groups, subjects received a single subretinal 200-microL administration of 5 x 1010 vector genomes/mL or 1.5 x 1011 vg/mL, while the control group remained untreated. The ArMaDa clinical trial for OCU410 is being performed at 14 retinal surgery centers across the U.S.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCGN:
- Largest borrow rate increases among liquid names
- Ocugen’s OCU400 granted positive opinion by EMA in retinitis pigmentosa
- Ocugen files to sell 57.54M shares of common stock for holders
- Ocugen announces IND in effect after FDA review
- Ocugen announces first patient dosed in Phase 1 OCU200 trial for DME